Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | FPR3 | P25089 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 2/20 | 0.45 |
| ▸ | CCR2 | P41597 | 10/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30117007 | 0.95 | CYP3A4 (0.47) | CYP3A4ALDH1A1FPR3FPR2MTOR | |
| SCHEMBL30117022 | 0.84 | MLYCD (0.49) | CYP3A4 | |
| SCHEMBL30116998 | 0.79 | SMN1; SMN2 (0.36) | CYP3A4CCR2HTT | |
| SCHEMBL26633839 | 0.79 | EPHX1 (0.50) | ALDH1A1 | |
| SCHEMBL30116993 | 0.79 | MLYCD (0.51) | CYP3A4HTT | |
| SCHEMBL30116941 | 0.78 | P2RX7 (0.47) | FPR3FPR2HTT | |
| SCHEMBL30116947 | 0.78 | FPR3 (0.46) | FPR3FPR2 | |
| SCHEMBL30116953 | 0.76 | KMT2A (0.39) | FPR3FPR2MTOR | |
| SCHEMBL25205210 | 0.75 | EPHX1 (0.44) | HTTNAMPT | |
| SCHEMBL13452941 | 0.74 | MTOR (0.54) | CYP3A4ALDH1A1MTORHTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115461327-A | Spiro urea derivatives | 爱杜西亚药品有限公司 | 2022-12-09 | — | — | CN | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| CN-115461327-A | Spiro urea derivatives | 爱杜西亚药品有限公司 | 2022-12-09 | — | — | CN | disclosed |